dual role of tgfβ in crc : tgfβ/smad4, crc, emt ......2019/05/03 · worldwide. in saudi arabia,...
TRANSCRIPT
1
TGFβ Induced SMAD4 Dependent Apoptosis Proceeded by EMT in CRC
Abdul K. Siraj1*, Poyil Pratheeshkumar1*, Sasidharan Padmaja Divya1, Sandeep Kumar
Parvathareddy1, Rong Bu1, Tariq Masoodi1, Yan Kong1, Saravanan Thangavel1, Nasser
Al-Sanea2, Luai H Ashari2, Alaa Abduljabbar2, Samar Alhomoud2, Fouad Al-Dayel3 and
Khawla S. Al-Kuraya1#
1Human Cancer Genomic Research, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia. 2Department of Surgery, Colorectal Unit, Riyadh, Saudi Arabia. 3Department of Pathology, King Faisal Specialist Hospital and Research Centre, P.O. Box 3354, Riyadh, 11211, Saudi Arabia. *These authors have contributed equally
Running Title: Dual role of TGFβ in CRC
Keywords: TGFβ/Smad4, CRC, EMT, Apoptosis, KLF5, Sox4
Additional information.
Financial Support: Authors declare that there is no funding information to be disclosed
for this manuscript.
Conflicts of interest: The authors declare no potential conflicts of interest.
Word Count: Abstract: 208, Total word count (introduction to discussion): 3900
Total number of Tables: 1
Total number of Figures: 5
#Corresponding author and to whom reprints should be addressed:
Khawla S. Al-Kuraya, MD, FCAP Human Cancer Genomic Research, Research center King Faisal Specialist Hospital and Research Cancer MBC#98-16, P.O. Box 3354, Riyadh 11211 Saudi Arabia Tel; (966)-1-205-5167; Fax (966)-1-205-5170 Email: [email protected]
on September 30, 2020. © 2019 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 3, 2019; DOI: 10.1158/1535-7163.MCT-18-1378
2
ABSTRACT
Colorectal cancer (CRC) is one of the leading cause of cancer-related deaths
Worldwide. In Saudi Arabia, CRC is more aggressive and presents at younger age,
warranting new treatment strategies. Role of TGFβ/Smad4 signaling pathway in
initiation and progression of CRC is well documented. Current study examined the role
of TGFβ/Smad4 signaling pathway in a large cohort of Saudi CRC, followed by in vitro
analysis to dissect the dual role of TGFβ on inducing epithelial to mesenchymal
transition (EMT) and apoptosis. Our study demonstrated high frequency of Smad4
alterations with low expression of Smad4 protein identifying a sub-group of aggressive
CRC to be an independent marker for poor prognosis. Functional studies using CRC
cells show that TGFβ induces Smad4 dependent EMT followed by apoptosis. Induction
of mesenchymal transcriptional factors, Snail1 and Zeb1 was essential for TGFβ-
induced apoptosis. Our results indicate that KLF5 acts as an oncogene in CRC cells
regardless of Smad4 expression and inhibition of KLF5 is requisite for TGFβ-induced
apoptosis. Furthermore, TGFβ/Smad4 signal inhibits the transcription of KLF5 that in
turn switches Sox4 from tumor promoter to suppressor. A high incidence of Smad4
alterations were found in the Saudi CRC patients. Functional study results indicate that
TGFβ induces Smad4 dependent EMT followed by apoptosis in CRC cells.
on September 30, 2020. © 2019 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 3, 2019; DOI: 10.1158/1535-7163.MCT-18-1378
3
INTRODUCTION
Colorectal cancer (CRC) is one of the most common malignancy and the second
leading cause of death by cancer in Western populations (1). However, there have been
remarkable changes in the rate of CRC incidence and mortality over the past few
decades in other ethnic population (2). In Saudi Arabia, CRC presents the number one
cancer affecting Saudi males and the third most common among females (3). Several
studies also have shown that CRC affecting Saudi population tend to be more
aggressive and present with high stage (4,5). CRC has a complex pathogenesis
involving multiple genetic and epigenetic alterations caused by somatic mutations that
lead to uncontrolled tumor cell proliferation, invasiveness and distant metastatic
potential (6,7).
Epithelial to mesenchymal transition (EMT) is a bidirectional process by which epithelial
cells lose their cell polarity and cell-cell adhesion, and gain a motile mesenchymal cell
phenotype that is believed to cause metastasis (8). Furthermore, EMT has been shown
to be attributed to chemotherapy resistance and enabling cancer cell survival (9). One
of the well-known inducer of EMT is transforming growth factor β (TGFβ) (10,11).
TGFβ/Smad4 signaling pathway control the signal transduction from cell membrane to
nucleus and is responsible for many important cellular processes such as tumor
initiation, progression, apoptosis and migration (12).
Although TGFβ is one of the potent inducer of EMT, it has paradoxical affect as tumor
growth suppressor by inducing cell cycle arrest and apoptosis in early stages of tumor
on September 30, 2020. © 2019 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 3, 2019; DOI: 10.1158/1535-7163.MCT-18-1378
4
formation (13). As the main mediator of canonical TGFβ signaling pathway, Smad4
plays pivotal role in the switch of TGFβ function on tumorigenesis (14). Smad4 is a key
mediator of the TGFβ signaling and act as tumor suppressor in CRC. Inactivation of
Smad4 at the gene or protein level is associated with progression of several types of
tumors including CRC (15-17).
Loss of Smad4 protein expression is found in 20% to 40% of CRC cases and strongly
correlated with poor prognosis of CRC patients (17-21). Studies also showed that
Smad4 has been mutated in about 15% of CRC tumors (22). However, data of Smad4
alteration in Middle Eastern CRC is limited (23,24). Therefore, we sought to explore the
role of Smad4 inactivation in a large cohort of CRC patients from Saudi Arabia and its
prognostic value in this ethnic group. Furthermore, a recent study has shed light on the
dichotomous effect of TGFβ/Smad4 signaling in pancreatic ductal adenocarcinoma
(PDA) (25) and its role in EMT and apoptosis. They revealed interesting results that
TGFβ induces PDA cells to undergo Smad4-dependent EMT followed by apoptosis.
In this study, we identified high incidence of Smad4 alterations (mutation, deletion and
low expression) in CRC in Saudi Arabia, a country with a particularly high incidence of
CRC developing at younger age, suggesting a potential role in CRC pathogenesis.
Interestingly, low expression of Smad4 was an independent poor prognostic marker.
Furthermore, functional analysis of relevant CRC cell lines support previously reported
role of TGFβ/Smad4 on inducing EMT and expression of mesenchymal markers Snail,
Twist and Zeb and highlighted the role of Smad4 deficiency in mediating drug
resistance (26-28). Similar to the observed role of TGFβ/Smad4 in PDA, this study also
on September 30, 2020. © 2019 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 3, 2019; DOI: 10.1158/1535-7163.MCT-18-1378
5
revealed that TGFβ /Smad4 signal inhibit the transcription of KLF5. Taken together, our
study demonstrate that TGFβ induces Smad4 dependent EMT followed by apoptosis in
CRC cells. This study further highlights the potential therapeutic role of KLF5 inhibition
in CRC treatment.
MATERIALS AND METHODS
Clinical Samples
A total of 1050 archival tissue samples from patients diagnosed with CRC at the King
Faisal Specialist Hospital and Research Centre were collected from Department of
Pathology. Detailed clinicopathological data were noted from case records and
summarized in Supplementary Table S1. Of these 1050 cases, 426 cases were
subjected to targeted capture sequencing. All samples were obtained from patients with
approval from Institutional Review Board of the hospital. For the study, waiver of
consent was obtained for archived paraffin tissue blocks from Research Advisory
Council (RAC) under project RAC#2170 025.
Tissue microarray and immunohistochemical evaluation
All samples were analyzed in a tissue microarray (TMA) format. TMA construction was
performed as described earlier (29). Briefly, tissue cylinders with a diameter of 0.6 mm
were punched from representative tumor regions of each donor tissue block and
brought into recipient paraffin block using a modified semiautomatic robotic precision
instrument (Beecher Instruments, Woodland, WI). Two cores of CRC were arrayed from
on September 30, 2020. © 2019 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 3, 2019; DOI: 10.1158/1535-7163.MCT-18-1378
6
each case. Standard protocol was followed for IHC staining, details of which are
provided in Supplementary Materials and Methods.
Smad4 immunohistochemical expression was seen predominantly in the nuclear
compartment and nuclear expression was quantified using the intensity score as
described previously (17). Briefly, the intensity of nuclear staining in the tumor cells
were scored from 0 to 4, with score 0 indicating absent Smad4 staining and score 4
indicating highest intensity of staining. Cases showing ≥3+ intensity score were
considered as normal for Smad4 expression. Score 0-2 were considered as low
expression of Smad4.
Tissue Culture Experiments
All human CRC cell lines; CX-1, CACO-2, HCT116, COLO-320, HCT15, DLD1, HT29,
SW480 and LOVO were purchased from ATCC and cultured in RPMI-1640 media
containing 10% fetal bovine serum (FBS), 100 U/ml penicillin, 100 U/ml streptomycin at
370 C in a humidified atmosphere containing 5% CO2. Authentication of all cell lines
were performed in house using short tandem repeats (STR) PCR. The results were
similar to the published data. All treatment experiments were performed in reduced FBS
(2%) condition. Apoptosis analysis was performed using annexinV/PI dual staining and
measured by flow cytometry as previously described (30). Information of antibodies
used for western blotting are listed in Supplementary Materials and Methods.
on September 30, 2020. © 2019 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 3, 2019; DOI: 10.1158/1535-7163.MCT-18-1378
7
Plasmid and Transfection
Plasmid DNA encoding human KLF5 and shRNA’s targeting human Snail1, Zeb1 and
KLF5 were purchased from Origene (Rockville, MD). The overexpression of KLF5 and
knockdown of Snail1, Zeb1 and KLF5 in CRC cells were performed using
Lipofectamine™2000 (Invitrogen, Carlsbad, CA) according to the manufacturer's
protocol. Briefly, CRC cells were seeded in 6-well culture plates; when approximately
50% confluent, cells were transfected with 4 μg plasmid. Stable overexpression clones
resistant to G418 and stable knockdown clones resistant to puromycin were isolated;
overexpression of KLF5 and knockdown of Snail1, Zeb1 and KLF5 protein production
were confirmed by immunoblotting.
Immunofluorescence analysis
Immunofluorescence assay was performed as described previously (31). Briefly, CRC
cells grown on glass coverslips in 6-well plates and fixed with ice-cold methanol. After
permeabilization with 0.2% Triton X-100 and blocking with 5% horse serum in PBS
solution, cells were stained with antibodies to Smad4 (1:100), or E-cadherin (1:200) for
1 h at 37 °C. After washing, cells were incubated with fluorescent-conjugated secondary
antibodies and mounted using DAPI. The cells were visualized using Olympus BX63
fluorescence microscope.
on September 30, 2020. © 2019 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 3, 2019; DOI: 10.1158/1535-7163.MCT-18-1378
8
Sphere forming assay
Cells (500/well) were plated on Corning 24-well ultra-low attachment plates (Sigma-
Aldrich) grown in serum free DMEM-F12 (ATCC) supplemented with B27 (Thermo
Fisher), 20 ng/ml epidermal growth factor (Sigma-Aldrich), 0.4% bovine serum albumin
(Sigma-Aldrich) and 4 μg/ml insulin (Sigma-Aldrich). Fresh medium was supplemented
every 2 days. The spheroids were counted and photographed at day 14. For secondary
spheroid formation, the primary spheroids were dissociated into single cells, and
cultured on 24-well ultra-low attachment plates using spheroid culture medium for
another 10 days.
Statistical analysis
Contingency table analysis and 2 tests were used to study the relationship between
clinico-pathological variables and Smad4 mutation/expression. Survival curves were
generated using the Kaplan-Meier method, with significance evaluated using the
Mantel-Cox log-rank test. The limit of significance for all analyses was defined as a P-
value of < 0.05; two-sided tests were used in the calculations. The JMP11.0 (SAS
Institute, Inc., Cary, NC) software package was used for data analyses.
For all functional studies, data are expressed as the mean ± SD of triplicate
samples and was repeated for at least two separate experiments. Statistical analysis
was performed using one-way analysis of variance (ANOVA), and p<0.05 was
considered statistically significant.
on September 30, 2020. © 2019 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 3, 2019; DOI: 10.1158/1535-7163.MCT-18-1378
9
RESULTS
Clinico-pathological data
The characteristics of the 1050 CRC patients are summarized in Supplementary Table
S1. The median age at the time of surgery was 56 years (inter quartile range [IQR], 47.0
-68.0 years) with a male: female ratio of 1.1. Most of the tumors were located in the left
colon (79.7%). 77.9% of patients had a moderately differentiated tumor and 51% were
either stage III or stage IV.
Smad4 mutation and their clinico-pathological correlation
We first performed high depth capture sequencing of 426 CRC cases, and found 63
mutations in 13.6% of cases. Sanger Sequencing confirmed 54 somatic mutations
present in 12.2% (52/426) CRC cases (Supplementary Fig. S1A). Out of these, 68.5%,
18.5%, 11% and 2% were missense, stop-gained, frame-shift and inframe mutations
respectively (Supplementary Table S2). The Smad4 mutation was significantly
associated with low Smad4 protein expression examined by IHC (p=0.0032). However,
no association was found between Smad4 mutation and 5 years overall survival
(Supplementary Table S3).
ACCESSION NUMBER
The target capture sequencing data of 426 tumors have been deposited to the
European Nucleotide Archive (ENA) with accession number PRJEB32337.
on September 30, 2020. © 2019 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 3, 2019; DOI: 10.1158/1535-7163.MCT-18-1378
10
Smad4 deletion on FISH and its correlation with clinico-pathological parameters
We also performed the FISH assay to examine the Smad4 deletion in the primary tumor
tissues of CRC samples (Supplementary Fig. S1B). In our series of 1050 CRC cases,
FISH analysis was interpretable in 991 cases. TMA for 59 cases were non-
representative due to lack of tumor cells. Of the cases analyzed, only Smad4 gene
deletion was detected in 4.2% (44) cases of CRC. Interestingly, chromosome 18q
monosomy (only one Smad4 signal and one CEN18q signal) was detected in 559
(53.2%) cases (Supplementary Table S4a). Altogether, Smad4 deletion was identified in
603 (60.8%) of our cohort, and was significantly associated with distant metastasis (p =
0.0247) and low Smad4 protein expression (p < 0.0001). Smad4 deletion was also
found to be significantly associated with MSS tumor (p < 0.0001), which is in agreement
with previous reports (32,33) (Supplementary Table S4b)
Low expression of Smad4 protein is associated with poor prognosis
Of the 1050 colorectal cancer cases investigated by immunohistochemistry, low
expression of Smad4 was noted in 67.1% (680/1013) of cases by IHC (Supplementary
Fig. S1C). Thirty-seven cases were non-interpretable due to loss of tissue cores or
absent tumor cells in core. The staining pattern ranged from absent staining to intense
4+ nuclear staining. Low expression of Smad4 was found to be significantly associated
with poor prognostic markers such as larger tumors (T3, p = 0.0008), lymph node
involvement (p=0.0006), TNM stage IV tumors (p = 0.0012), Dukes’ stage C (p =
0.0006) and MSS tumors (p < 0.0001) (Table 1).
on September 30, 2020. © 2019 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 3, 2019; DOI: 10.1158/1535-7163.MCT-18-1378
11
Of particular importance was the association of low Smad4 protein expression with poor
5-year overall survival on univariate analysis using Kaplan-Meier curve (71.6% vs
78.9%, X2 = 7.33, p = 0.0068, Supplementary Fig. S1D). On multivariate analysis using
Cox proportional hazards regression model after adjusting for possible confounders of
survival, low expression of Smad4 was indeed found to be an independent poor
prognostic marker (HR = 1.77; 95% CI = 1.26–2.55; p = 0.0009).
Smad4 alterations and their associations
Smad4 alterations (mutation or low expression or deletion by FISH) were noted in
82.2% (342/416) of our cases. A significant association was noted between Smad4
alteration and lymph node involvement (p = 0.0439) as well as with MSS tumors (p <
0.0001) (Supplementary Table S5).
TGFβ induces Smad4 dependent apoptosis in CRC cells
To explore the role of Smad4 in TGFβ induced apoptosis in CRC cells, we analyzed the
expression of Smad4 in a panel of nine CRC cell lines by immunoblotting (Fig. 1A).
Based on Smad4 expression, we selected two CRC cells lines, HCT116 and DLD1 that
had over-expression of Smad4 as well as two other cell lines, HT29 and SW480 that
had negligible Smad4 expression for further experimentation. Smad4 abundance in
these cells was also verified by immunofluorescence analysis (Fig. 1B). We investigated
the effect of TGFβ on inhibiting cell viability and inducing apoptosis in these cells. There
was inhibition of cell viability and induction of apoptosis in both CRC cell lines that had
overexpression of Smad4; however, TGFβ has no effect on cell viability and apoptosis
in Smad4 low expressing cells (Fig. 1C-F).
on September 30, 2020. © 2019 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 3, 2019; DOI: 10.1158/1535-7163.MCT-18-1378
12
To verify the role of Smad4 in TGFβ induced cell death, we knockout Smad4 in Smad4
proficient cells (HCT116 and DLD1) (Supplementary Fig. S2A) followed by treatment
with TGFβ for 48 hours and analyzed cell proliferation and apoptosis. Silencing of
Smad4 significantly suppressed TGFβ induced inhibition of cell proliferation as
confirmed by clonogenic assay (Supplementary Fig. S2B-C). As shown in
supplementary Fig. S2D, Smad4 knockout cells became resistant to TGFβ treatment as
compared to Smad4 proficient control. Furthermore, we stably overexpressed Smad4 in
Smad4 deficient cells (HT29 and SW480) (Supplementary Fig. S2E). Forced expression
of Smad4 significantly decreased cell proliferation after treatment with TGFβ
(Supplementary Fig. S2F-G). Overexpression of Smad4 in HT29 and SW480 cells
became sensitive to TGFβ treatment as compared with cells transfected with empty
vector (Supplementary Fig. S2H).
TGFβ induces EMT followed by apoptosis in CRC cells
TGFβ has been known to induce both EMT and apoptosis in vitro (34,35). To
understand these events in detail, we treated Smad4 proficient and Smad4 deficient
CRC cells with TGFβ at different time points. As shown in Fig. 2A, Smad4 proficient
CRC cells lost cellular polarity and started forming elongated spindle-like protrusions
after 12 hours of TGFβ treatment. From 24-48 hours of TGFβ treatment, most spindle
like Smad4 proficient cells began to shrink and started dying. In contrast, Smad4
deficient cells retained its original morphology with negligible cell death throughout this
period (Fig. 2A). Immunofluorescence analysis showed a downregulation of E-cadherin
on September 30, 2020. © 2019 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 3, 2019; DOI: 10.1158/1535-7163.MCT-18-1378
13
expression after TGFβ treatment in Smad4 proficient cells, whereas the Smad4
deficient cells retained E-cadherin expression (Fig. 2B).
As shown in Fig. 2C, there was a time course increase in apoptosis following treatment
with TGFβ after 24 hours in Smad4 proficient cells confirming that this cell death was
due to apoptosis. However, TGFβ had no effect on Smad4 deficient cells (Fig. 2C). We
also investigated the expression of E-cadherin and apoptotic protein markers after
TGFβ treatment at different time points (24 and 48 hours) on these cells by immuno-
blotting. As shown in Fig. 2D, treatment of TGFβ successfully down-regulated E-
cadherin expression and induced the cleavage of caspase-3 in Smad4 proficient CRC
cells, whereas the expression of E-cadherin and caspase-3 remained unchanged in
Smad4 deficient cells (Fig. 2D). Together, these findings suggest that TGFβ induces
Smad4-dependent EMT followed by apoptosis in CRC cells.
Snail1 and Zeb1 promote EMT and apoptosis
Transcription factors, Snail1 and Zeb1 plays a key role in initiating TGFβ induced EMT
process (36,37). As shown in Fig. 3A-B, TGFβ treatment prominently induced the
expression of Snail1 and Zeb1 after 48 hours in Smad4 proficient CRC cells but not in
Smad4 deficient cells. Silencing of Snail1 and Zeb1 in Smad4 proficient cells markedly
inhibited the TGFβ-induced E-cadherin downregulation (Fig. 3C). Besides, knockdown
of Snail1 and Zeb1 suppressed the induction of EMT-like morphological changes by
TGFβ in Smad4 proficient cells (Fig. 3D). Next, we sought to determine the role of
Snail1 and Zeb1 in TGFβ-induced apoptosis. As shown in Fig. 3E-F, silencing of Snail1
on September 30, 2020. © 2019 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 3, 2019; DOI: 10.1158/1535-7163.MCT-18-1378
14
and Zeb1 significantly inhibited the TGFβ-induced apoptosis in Smad4 proficient cells,
showing the essential role of these transcriptional factors on TGFβ-induced apoptosis.
Sox4 is required for TGFβ driven apoptosis
Sox4 expression has shown to be elevated in a wide variety of human cancers (38-40).
To understand the role of Sox4 in TGFβ driven apoptosis, we silenced Sox4 in Smad4
proficient cells using two different shRNA’s and treated with TGFβ for 48 hours and
analyzed apoptosis. As shown in Fig. 4A, knockdown of Sox4 significantly suppressed
TGFβ-induced apoptosis in Smad4 proficient CRC cells. There was no further
significant increase in apoptosis even after addition of 5-FU in Sox4 depleted cells (Fig.
4A). This data clearly demonstrate that Sox4 is essential for TGFβ driven apoptosis in
Smad4 proficient cells. Next, we tested the role of Sox4 in TGFβ-induced EMT.
Knockdown of Sox4 had no effect on EMT morphology (Fig. 4B) or E-cadherin
expression (Fig. 4C). There was an increase in Sox4 expression in scramble control
cells after TGFβ treatment (Fig. 4C). Moreover, silencing of Snail1 and Zeb1 had no
effect on Sox4 expression (Fig. 4D). These results show that Sox4 has no role in TGFβ-
induced EMT. To test the role of Sox4 in spheroid growth, we generated spheroids from
Smad4 proficient cells and stemness of the spheroids were confirmed using stem cell
markers (Fig. 4E). Next, we determined the expression of Sox4 in adherent and
spheroid cells with and without TGFβ treatment. Cells grown as spheroids showed
higher Sox4 expression than cells grown in adherent conditions (Fig. 4F). Moreover,
there was an increase in Sox4 expression in both cells after TGFβ treatment (Fig. 4F).
To verify the role of Sox4 in spheroid growth, we silenced Sox4 in Smad4 proficient
on September 30, 2020. © 2019 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 3, 2019; DOI: 10.1158/1535-7163.MCT-18-1378
15
cells and grown in spheroid medium. As shown in Fig. 4G-H, silencing of Sox4
significantly decreased the spheroid growth. This data was further verified using
immunoblotting, where knockdown of Sox4 markedly decreased the stem cell marker
proteins expression in spheroids (Fig. 4I). Above results indicate that Sox4 acts as a
tumor initiator in Smad4 proficient cells. Taken together, these data suggest that during
TGFβ-induced EMT, Sox4 switches its function from pro-tumorigenic to pro-apoptotic.
Silencing of KLF5 sensitizes Smad4 deficient cells to TGFβ -induced apoptosis
KLF5 has been shown to promote cancer cell proliferation in several cancers including
CRC (41,42). To study the role KLF5 in TGFβ-induced apoptosis, we treated Smad4
proficient and Smad4 deficient cells with TGFβ for 48 hours and analyzed the
expression of KLF5 by immunoblotting. As shown in Fig. 5A, there was a prominent
inhibition of KLF5 expression after TGFβ treatment in Smad4 proficient cells, but the
KLF5 expression remained unchanged in Smad4 deficient cells. The basal expression
of KLF5 was relatively higher in Smad4 deficient cells than Smad4 proficient cells (Fig.
5A). Next, we silenced KLF5 in Smad4 deficient cells using two different shRNA’s and
treated with TGFβ and 5-FU either alone or in combination for 48 hours and analyzed
apoptosis. As shown in Fig. 5B, silencing of KLF5 markedly increased TGFβ-induced
apoptosis in Smad4 deficient CRC cells. Furthermore, treatment of 5-FU significantly
sensitized the KLF5 depleted cells (Fig. 5B). This data clearly demonstrate that
inhibition of KLF5 is essential for TGFβ driven apoptosis. This finding was in
concordance with recent reports in pancreatic cancer cells (25). David et al., reported
that TGFβ induced EMT inhibits KLF5 in Smad4 proficient cells and induce apoptosis
(25). To test the role of KLF5 in spheroid growth, we generated spheroids from Smad4
on September 30, 2020. © 2019 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 3, 2019; DOI: 10.1158/1535-7163.MCT-18-1378
16
deficient cells and stemness of the spheroids were confirmed using stem cell markers
(Fig. 5C). To test the role of KLF5 in spheroid growth, we silenced KLF5 in Smad4
deficient cells and grown in spheroid medium. Silencing of KLF5 significantly decreased
the spheroid growth (Fig. 5D-E) and stemness properties (Fig. 5F). Above results,
clearly indicate that KLF5 acts as an oncogene in CRC cells regardless of Smad4
expression and inhibition of KLF5 is essential for TGFβ induced apoptosis.
To test the role KLF5 in TGFβ induced EMT, we stably overexpressed KLF5 in Smad4
proficient cells, treated with TGFβ, and analyzed the E-cadherin expression. As shown
in Fig. 5G, overexpression of KLF5 inhibited TGFβ-induced downregulation of E-
cadherin in Smad4 proficient cells. This data evidently demonstrate the association
between KLF5 and EMT. Next, we tested the effect of KLF5 overexpression in TGFβ
induced apoptosis. Forced expression of KLF5 significantly inhibited TGFβ-induced
apoptosis in Smad4 proficient cells (Fig. 5H). Above results, clearly exhibit the
oncogenic function of KLF5. Finally, we silenced both Sox4 and KLF5 in Smad4
deficient cells to confirm the link between these proteins in TGFβ-induced apoptosis. As
shown in Fig. 5I, depletion of KLF5 promotes apoptosis in Smad4 deficient cells after
TGFβ treatment, whereas there was a significant inhibition of apoptosis on Sox4
depletion. All these results indicate that Sox4 promote apoptosis upon KLF5 depletion.
DISCUSSION
In the current study, we used a large cohort of clinical samples to address the clinical
significance of Smad4 alterations in Saudi CRC. We evaluated the Smad4 protein
expression in more than 1000 Saudi CRC patients as well as genomic mutation and
on September 30, 2020. © 2019 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 3, 2019; DOI: 10.1158/1535-7163.MCT-18-1378
17
gene deletion. The frequency of Smad4 alteration was similar to what has been
reported in CRC from other ethnicities (17,23,43-45). Consistent with previous reports,
loss of Smad4 expression exhibited strong correlation to poor overall survival in CRC
patients (46-48). Importantly, we show that low levels of Smad4 protein can identify a
subset of patients with Dukes’ C CRC who have a high probability of recurrence
following potentially curative surgery and 5-FU based adjuvant chemotherapy.
The role of TGFβ signaling in CRC progression and prognosis is very complex and has
previously shown bilateral dependence based on Smad4 status (49). Smad4 is an
important mediator of TGFβ signaling pathway and function as a tumor suppressor gene
in CRC (50). Our study shows that Smad4 expression was reduced significantly with
advancing tumor stage (Table 1). Our in vitro results using CRC cell lines identified a
mechanistic basis for duality of TGFβ in CRC. We show that under conditions of TGFβ
stimulation, presence of the common transactivator protein Smad4 in CRC cells
undergo apoptosis, while in its absence cancer cells promote tumor growth.
Interestingly, in agreement with recent report (25), TGFβ-induced Smad4 dependent
apoptosis is preceded by EMT. Moreover, TGFβ-induced activation of Snail1 and Zeb1
were required for EMT-related apoptosis. TGFβ-induced EMT is generally considered
as a pro-tumorigenic event. However, our study demonstrates that TGFβ exerts tumor
suppression in CRC cells by inducing EMT signal, which inhibits the transcription of
KLF5 that in turn switches Sox4 from tumor promoter to suppressor.
Our study demonstrated the essential role of Sox4 on inducing TGFβ/Smad4-mediated
apoptosis. However, Sox4 showed no direct effect on inducing EMT. Sox4 act as a
on September 30, 2020. © 2019 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 3, 2019; DOI: 10.1158/1535-7163.MCT-18-1378
18
tumor suppressor in those cells that undergo a TGFβ/Smad4 induced EMT, showing
that EMT switches Sox4 function from pro-tumorigenic to pro-apoptotic in CRC cells.
Interestingly, knockdown of KLF5 was sufficient to revert pro-tumorigenic function of
TGFβ and induce apoptosis in Smad4 deficient cells. Furthermore, we show that TGFβ-
mediated EMT downregulates KLF5 expression in Smad4 proficient cells that convert
Sox4 from anti-apoptotic to pro-apoptotic. These data indicate that KLF5 may be a vital
determinant of Sox4 function in CRC. Moreover, forced expression of KLF5 in Smad4
proficient CRC cells prominently inhibited TGFβ-induced EMT and apoptosis, further
confirming the oncogenic function of KLF5.
EMT has been shown previously to contribute to chemoresistance in various epithelial
cancers (51,52). Our data show that Smad4 proficient CRC cells were sensitive to 5-FU
chemotherapy even under TGFβ stimulation, while Smad4 deficient cells were
resistance to 5-FU chemotherapy. However, targeted inhibition of KLF5 using shRNA in
Smad4 deficient CRC cells were able to revert the chemoresistance under TGF
stimulation. This is important from translational stand point as it might suggest the
possibility of therapeutic value of inhibiting KLF5 in Smad4 deficient CRC patients.
However, additional studies are needed to further validate these findings and move
KLF5 inhibitor to preclinical testing.
In conclusion, our results show that Smad4 alteration is frequent in CRC from Middle
Eastern ethnicity and can identify patients at advanced stage (Dukes’ C) and
significantly poor outcome. Our functional studies in CRC cells reinforce the role of
on September 30, 2020. © 2019 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 3, 2019; DOI: 10.1158/1535-7163.MCT-18-1378
19
Smad4 in TGFβ-induced EMT signaling cascade. Furthermore, our results revealed that
TGFβ/Smsd4 signal inhibits the transcription of KLF5 that in turn switches Sox4 from
tumor promoter to suppressor. Therefore, we conclude that TGFβ induces Smad4
dependent lethal EMT in CRC cells.
ACKNOWLEDGMENTS
We thank Dr. Maqbool Ahmed, Roxanne Melosantos, Rafia Begum, Wael Haqawi,
Zeeshan Qadri, Dionne Rae Rala, Ingrid Francesca Victoria, Maha Al Rasheed, for
technical assistance.
on September 30, 2020. © 2019 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 3, 2019; DOI: 10.1158/1535-7163.MCT-18-1378
20
REFERENCES
1. Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RG, Barzi A, et al. Colorectal cancer statistics, 2017. CA: a cancer journal for clinicians 2017;67(3):177-93.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA: a cancer journal for clinicians 2013;63(1):11-30.
3. Al-Shahrani Z, Al-Rawaji A, Al-Madouj A, Hayder M, Al-Zahrani A, Al-Mutlaq H, et al. Cancer Incidence Report Saudi Arabia 2014. Saudi Cancer Registry 2017(September):1-81.
4. Al-Ahwal MS, Shafik YH, Al-Ahwal HM. First national survival data for colorectal cancer among Saudis between 1994 and 2004: what’s next? BMC Public Health 2013;13(1):73.
5. Alsanea N, Abduljabbar AS, Alhomoud S, Ashari LH, Hibbert D, Bazarbashi S. Colorectal cancer in Saudi Arabia: incidence, survival, demographics and implications for national policies. Annals of Saudi medicine 2015;35(3):196-202.
6. Beg S, Siraj AK, Prabhakaran S, Bu R, Al‐Rasheed M, Sultana M, et al. Molecular markers and pathway analysis of colorectal carcinoma in the Middle East. Cancer 2015;121(21):3799-808.
7. George B, Kopetz S. Predictive and prognostic markers in colorectal cancer. Current oncology reports 2011;13(3):206-15.
8. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. The Journal of clinical investigation 2009;119(6):1420-8.
9. Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 2010;29(34):4741.
10. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. cell 2011;144(5):646-74. 11. Sporn MB, Roberts AB, Wakefield LM, Assoian RK. Transforming growth factor-beta: biological
function and chemical structure. Science 1986;233(4763):532-4. 12. Shi Y, Massagué J. Mechanisms of TGF-β signaling from cell membrane to the nucleus. Cell
2003;113(6):685-700. 13. Connolly EC, Freimuth J, Akhurst RJ. Complexities of TGF-β targeted cancer therapy.
International journal of biological sciences 2012;8(7):964. 14. Zhao M, Mishra L, Deng C-X. The role of TGF-β/SMAD4 signaling in cancer. International journal
of biological sciences 2018;14(2):111. 15. Fukuchi M, Masuda N, Miyazaki T, Nakajima M, Osawa H, Kato H, et al. Decreased Smad4
expression in the transforming growth factor‐β signaling pathway during progression of esophageal squamous cell carcinoma. Cancer 2002;95(4):737-43.
16. Kojima K, Vickers SM, Adsay NV, Jhala NC, Kim H-G, Schoeb TR, et al. Inactivation of Smad4 accelerates KrasG12D-mediated pancreatic neoplasia. Cancer research 2007;67(17):8121-30.
17. Alazzouzi H, Alhopuro P, Salovaara R, Sammalkorpi H, Järvinen H, Mecklin J-P, et al. SMAD4 as a prognostic marker in colorectal cancer. Clinical Cancer Research 2005;11(7):2606-11.
18. Salovaara R, Roth S, Loukola A, Launonen V, Sistonen P, Avizienyte E, et al. Frequent loss of SMAD4/DPC4 protein in colorectal cancers. Gut 2002;51(1):56-9.
19. Roth AD, Delorenzi M, Tejpar S, Yan P, Klingbiel D, Fiocca R, et al. Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer. Journal of the National Cancer Institute 2012;104(21):1635-46.
20. Voorneveld PW, Jacobs RJ, Kodach LL, Hardwick JC. A meta-analysis of SMAD4 immunohistochemistry as a prognostic marker in colorectal cancer. Translational oncology 2015;8(1):18-24.
21. Shi Y, Hata A, Lo RS, Massague J, Pavletich NP. A structural basis for mutational inactivation of the tumour suppressor Smad4. Nature 1997;388(6637):87.
on September 30, 2020. © 2019 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 3, 2019; DOI: 10.1158/1535-7163.MCT-18-1378
21
22. Akhurst RJ, Derynck R. TGF-β signaling in cancer–a double-edged sword. Trends in cell biology 2001;11(11):S44-S51.
23. Dallol A, Buhmeida A, Al-Ahwal MS, Al-Maghrabi J, Bajouh O, Al-Khayyat S, et al. Clinical significance of frequent somatic mutations detected by high-throughput targeted sequencing in archived colorectal cancer samples. Journal of translational medicine 2016;14(1):118.
24. Al-Shamsi HO, Jones J, Fahmawi Y, Dahbour I, Tabash A, Abdel-Wahab R, et al. Molecular spectrum of KRAS, NRAS, BRAF, PIK3CA, TP53, and APC somatic gene mutations in Arab patients with colorectal cancer: determination of frequency and distribution pattern. Journal of gastrointestinal oncology 2016;7(6):882.
25. David CJ, Huang Y-H, Chen M, Su J, Zou Y, Bardeesy N, et al. TGF-β tumor suppression through a lethal EMT. Cell 2016;164(5):1015-30.
26. Bracken CP, Gregory PA, Kolesnikoff N, Bert AG, Wang J, Shannon MF, et al. A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition. Cancer research 2008;68(19):7846-54.
27. Vincent T, Neve EP, Johnson JR, Kukalev A, Rojo F, Albanell J, et al. A SNAIL1–SMAD3/4 transcriptional repressor complex promotes TGF-β mediated epithelial–mesenchymal transition. Nature cell biology 2009;11(8):943.
28. Thuault S, Valcourt U, Petersen M, Manfioletti G, Heldin C-H, Moustakas A. Transforming growth factor-β employs HMGA2 to elicit epithelial–mesenchymal transition. J cell Biol 2006;174(2):175-83.
29. Siraj A, Bavi P, Abubaker J, Jehan Z, Sultana M, Al‐Dayel F, et al. Genome‐wide expression analysis of Middle Eastern papillary thyroid cancer reveals c‐MET as a novel target for cancer therapy. The Journal of pathology 2007;213(2):190-9.
30. Ahmed M, Hussain AR, Bavi P, Ahmed SO, Al Sobhi SS, Al-Dayel F, et al. High prevalence of mTOR complex activity can be targeted using Torin2 in papillary thyroid carcinoma. Carcinogenesis 2014;35(7):1564-72 doi 10.1093/carcin/bgu051
bgu051 [pii]. 31. Al-Kuraya KS. MED12 is recurrently mutated in Middle Eastern colorectal cancer. Oncotarget
2018;67(4):663-71 doi 10.18632/oncotarget.24739
10.1136/gutjnl-2016-313334. 32. Isaksson‐Mettävainio M, Palmqvist R, Dahlin AM, Van Guelpen B, Rutegård J, Öberg Å, et al.
High SMAD4 levels appear in microsatellite instability and hypermethylated colon cancers, and indicate a better prognosis. International journal of cancer 2012;131(4):779-88.
33. Ogino S, Kawasaki T, Kirkner GJ, Ohnishi M, Fuchs CS. 18q loss of heterozygosity in microsatellite stable colorectal cancer is correlated with CpG island methylator phenotype-negative (CIMP-0) and inversely with CIMP-low and CIMP-high. BMC cancer 2007;7(1):72.
34. Xu J, Lamouille S, Derynck R. TGF-β-induced epithelial to mesenchymal transition. Cell research 2009;19(2):156.
35. Ramesh S, Wildey GM, Howe PH. Transforming growth factor β (TGFβ)-induced apoptosis: the rise and fall of Bim. Cell Cycle 2009;8(1):11-7.
36. Chanmee T, Ontong P, Mochizuki N, Kongtawelert P, Konno K, Itano N. Excessive Hyaluronan Production Promotes Acquisition of Cancer Stem Cell Signatures Through the Coordinated Regulation of Twist and the TGF-β-Snail Signaling Axis. Journal of Biological Chemistry 2014:jbc. M114. 564120.
37. Naber HP, Drabsch Y, Snaar-Jagalska BE, ten Dijke P, van Laar T. Snail and Slug, key regulators of TGF-β-induced EMT, are sufficient for the induction of single-cell invasion. Biochemical and biophysical research communications 2013;435(1):58-63.
on September 30, 2020. © 2019 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 3, 2019; DOI: 10.1158/1535-7163.MCT-18-1378
22
38. Aaboe M, Birkenkamp-Demtroder K, Wiuf C, Sørensen FB, Thykjaer T, Sauter G, et al. SOX4 expression in bladder carcinoma: clinical aspects and in vitro functional characterization. Cancer research 2006;66(7):3434-42.
39. Liu P, Ramachandran S, Seyed MA, Scharer CD, Laycock N, Dalton WB, et al. Sex-determining region Y box 4 is a transforming oncogene in human prostate cancer cells. Cancer research 2006;66(8):4011-9.
40. Hur W, Rhim H, Jung CK, Kim JD, Bae SH, Jang JW, et al. SOX4 overexpression regulates the p53-mediated apoptosis in hepatocellular carcinoma: clinical implication and functional analysis in vitro. Carcinogenesis 2010;31(7):1298-307.
41. Ma D, Chang L-Y, Zhao S, Zhao J-J, Xiong Y-J, Cao F-Y, et al. KLF5 promotes cervical cancer proliferation, migration and invasion in a manner partly dependent on TNFRSF11a expression. Scientific reports 2017;7(1):15683.
42. Jia L, Zhou Z, Liang H, Wu J, Shi P, Li F, et al. KLF5 promotes breast cancer proliferation, migration and invasion in part by upregulating the transcription of TNFAIP2. Oncogene 2016;35(16):2040.
43. Jia X, Shanmugam C, Paluri RK, Jhala NC, Behring MP, Katkoori VR, et al. Prognostic value of loss of heterozygosity and sub-cellular localization of SMAD4 varies with tumor stage in colorectal cancer. Oncotarget 2017;8(12):20198.
44. Garcia J, Duran A, Tabernero MD, Garcia Plaza A, Flores Corral T, Najera ML, et al. Numerical abnormalities of chromosomes 17 and 18 in sporadic colorectal cancer: Incidence and correlation with clinical and biological findings and the prognosis of the disease. Cytometry Part B: Clinical Cytometry: The Journal of the International Society for Analytical Cytology 2003;51(1):14-20.
45. Fleming NI, Jorissen RN, Mouradov D, Christie M, Sakthianandeswaren A, Palmieri M, et al. SMAD2, SMAD3 and SMAD4 mutations in colorectal cancer. Cancer research 2013;73(2):725-35.
46. Yan P, Klingbiel D, Saridaki Z, Ceppa P, Curto M, McKee T, et al. Reduced expression of SMAD4 is associated with poor survival in colon cancer. Clinical Cancer Research 2016:clincanres. 0939.2015.
47. Baraniskin A, Munding J, Schulmann K, Meier D, Porschen R, Arkenau H-T, et al. Prognostic value of reduced SMAD4 expression in patients with metastatic colorectal cancer under oxaliplatin-containing chemotherapy: a translational study of the AIO colorectal study group. Clinical colorectal cancer 2011;10(1):24-9.
48. Kozak MM, von Eyben R, Pai J, Vossler SR, Limaye M, Jayachandran P, et al. Smad4 inactivation predicts for worse prognosis and response to fluorouracil-based treatment in colorectal cancer. Journal of clinical pathology 2015;68(5):341-5.
49. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-β family signalling. Nature 2003;425(6958):577.
50. Network CGA. Comprehensive molecular portraits of human breast tumors. Nature 2012;490(7418):61.
51. Fischer KR, Durrans A, Lee S, Sheng J, Li F, Wong ST, et al. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature 2015;527(7579):472.
52. Elaskalani O, Razak NBA, Falasca M, Metharom P. Epithelial-mesenchymal transition as a therapeutic target for overcoming chemoresistance in pancreatic cancer. World journal of gastrointestinal oncology 2017;9(1):37.
on September 30, 2020. © 2019 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 3, 2019; DOI: 10.1158/1535-7163.MCT-18-1378
23
Table 1. Correlation of Smad4 IHC expression with clinico-pathological parameters in
colorectal carcinoma
Total Low Normal p value
N % N % N %
Total Number of Cases 1013 680 67.1 333 32.9
Age ≤ 50 years 332 33.0 220 66.3 112 33.7 0.7646 > 50 years 674 67.0 453 67.2 221 32.8
Sex Male 535 52.8 358 66.9 177 33.1 0.8795 Female 478 47.2 322 67.4 156 32.6
Tumour Site Left colon 800 80.8 548 68.5 252 31.5 0.0520 Right colon 190 19.2 116 61.0 74 39.0
Histological Type Adenocarcinoma 899 89.4 615 68.4 284 31.6 0.0039 Mucinous Carcinoma 107 10.6 58 54.2 49 45.8
pT T1 32 3.4 13 40.6 19 59.4 0.0008 T2 151 15.8 93 61.6 58 38.4 T3 681 71.2 477 70.0 204 30.0 T4 92 9.6 54 58.7 38 41.3
pN N0 484 50.5 297 61.4 187 38.6 0.0006 N1 303 31.7 225 74.3 78 25.7 N2 170 17.8 118 69.4 52 30.6
pM M0 849 87.1 558 65.7 291 34.3 0.1437 M1 126 12.9 91 72.2 35 27.8
TNM Stage I 127 13.1 68 53.5 59 46.5 0.0012 II 328 33.8 210 64.0 118 36.0 III 389 40.1 277 71.2 112 28.8 IV 126 13.0 91 72.2 35 27.8
Dukes’ Stage A 128 13.3 69 53.9 59 46.1 0.0006 B 325 33.7 210 64.6 115 35.4 C 386 40.0 280 72.5 106 27.5 D 126 13.0 91 72.2 35 27.8
Differentiation Well differentiated 102 10.3 61 59.8 41 40.2 0.0083 Moderate differentiated 786 79.1 545 69.3 241 30.7 Poor differentiated 105 10.6 59 56.2 46 43.8
MSI-IHC MSI-H 96 9.7 38 39.6 58 60.4 <0.0001 MSS 896 90.3 629 70.2 267 29.8
Smad4 Mutation Yes 52 12.6 43 82.7 9 17.3 0.0032 No 361 87.4 227 62.9 134 37.1
Smad4 FISH Monosomy/Deletion 577 60.8 427 74.0 150 26.0 <0.0001 Normal 372 39.2 215 57.8 157 42.2
Survival OS 5 Years 71.6 78.9 0.0068
on September 30, 2020. © 2019 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 3, 2019; DOI: 10.1158/1535-7163.MCT-18-1378
24
Figure Legends
Figure 1. TGFβ induces Smad4 dependent apoptosis in CRC cells. (A) Smad4
expression in a panel of CRC cell lines. Proteins were isolated from nine CRC cell lines
and immunoblotted with antibodies against Smad4 and GAPDH. (B) Representative
images of fluorescence immunostaining for Smad4 in four-selected CRC cell lines and
confirm results from western blot analysis. (C) CRC cells were treated with indicated
doses of TGFβ for 48 hours and cell viability was measured by MTT assay (D-E) CRC
cells were treated with indicated doses of TGFβ for 48 hours and clonogenic assay
were performed. Cells (6x102) after post treatment were seeded into each of three
dishes (60 mm diameter), and grown for an additional 10 days, then stained with crystal
violet (E). Colony numbers in the entire dish were counted. (F) CRC cells were treated
with indicated doses of TGFβ for 48 hours and cells were analyzed for apoptosis by flow
cytometry. Data presented in the bar graphs are the mean ± SD of three independent
experiments. *Indicates a statistically significant difference compared to control with p <
0.05.
Figure 2. TGFβ induces EMT followed by apoptosis. (A) Cell morphology under
microscope after treatment with TGFβ at different time-periods. (B)
Immunofluorescence analysis of EMT marker E-cadherin after treatment with TGFβ at
different time-periods. (C) CRC cells were treated with TGFβ at the indicated times and
cells were stained with flourescein-conjugated annexin-V and propidium iodide (PI) and
analyzed by flow cytometry. (D) CRC cells were treated with TGFβ at the indicated
on September 30, 2020. © 2019 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 3, 2019; DOI: 10.1158/1535-7163.MCT-18-1378
25
times and proteins were isolated and immunoblotted with antibodies against E-cadherin,
caspase-3, Smad4 and GAPDH.
Figure 3. Snail and Zeb1 promote EMT and apoptosis. (A-B) TGFβ induces
upregulation of Snail1 and Zeb1 expression in smad4 proficient cells but not in smad4
deficient CRC cells. CRC cells were treated with TGFβ for 48 hours and proteins were
isolated and immunoblotted with antibodies against Snail1, Zeb1 and GAPDH. (C)
Silencing of Snail1 and Zeb1 inhibits the TGFβ induced down-regulation of E-cadherin
in smad4 proficient cells. Smad4 proficient cells were transfected with Snail1 and Zeb1
shRNA’s and were treated with TGFβ for 48 hours. Proteins were isolated and
immunoblotted with antibodies against E-cadherin and GAPDH. (D) Cell morphology
under microscope after 48 hours of TGFβ treatment in smad4 proficient cells expressing
control shRNA’s, or shRNA’s targeting Snail1 and Zeb1. (E-F) Silencing of Snail1 and
Zeb1 inhibits the TGFβ induced apoptosis in smad4 proficient cell. Smad4 proficient
cells after transfection with Snail1 and Zeb1 shRNA’s were treated with TGFβ for 48
hours. Cells were stained with flourescein-conjugated annexin-V and propidium iodide
(PI) and analyzed for apoptosis by flow cytometry. Data presented in the bar graphs are
the mean ± SD of three independent experiments. *Indicates a statistically significant
difference compared to control with p < 0.05.
Figure 4. Sox4 is essential for TGFβ induced apoptosis. (A) Silencing of Sox4
inhibits the TGFβ induced apoptosis in smad4 proficient cells. Smad4 proficient cells
were transfected with Sox4 shRNA’s and were treated with TGFβ or TGFβ and 5-FU
on September 30, 2020. © 2019 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 3, 2019; DOI: 10.1158/1535-7163.MCT-18-1378
26
combination for 48 hours and cells were analyzed for apoptosis. (B-C) Silencing of Sox4
has no effect on TGFβ induced EMT in smad4 proficient cells. Smad4 proficient cells
were transfected with Sox4 shRNA’s and were treated with TGFβ for 48 hours. (B) Cell
morphology was photographed under microscope. (C) Proteins were isolated and
immunoblotted with antibodies against E-cadherin, Sox4 and GAPDH. (D) Silencing of
Snail1 and Zeb1 has no effect on Sox4. Smad4 proficient cells were transfected with
Snail1 and Zeb1 shRNA’s and were treated with TGFβ for 48 hours. Proteins were
isolated and immunoblotted with antibodies against Sox4 and GAPDH. (E) Isolation of
spheroid-forming cells from Smad4 proficient cells. Sphere forming assay was
performed by culturing cells (5 x 102 cells/well) in sphere medium for 14 days in 24-well
ultra-low attachment plates. Stemness property of the isolated spheroids was verified
using cancer stem cell markers by immunoblotting. (F) Sox4 expression in spheroids
and adherent cells after TGFβ for 48 hours treatment (G-H) Silencing of Sox4 inhibited
self-renewal ability of spheroids. Smad4 proficient cells were transfected with Sox4
shRNA. After transfection, cells were subjected to sphere forming assay. Spheroids in
the entire well were counted. (I) Silencing of Sox4 inhibited stemness of spheroids as
confirmed by immunoblotting using stem cell markers. Data presented in the bar graphs
are the mean ± SD of three independent experiments. *Indicates a statistically
significant difference compared to control with p < 0.05.
Figure 5. Silencing of KLF5 increases apoptosis in Smad4 deficient CRC cells. (A)
Downregulation of KLF5 expression after TGFβ treatment in smad4 proficient cells but
not in smad4 deficient cells. Smad4 proficient and smad4 deficient cells were treated
on September 30, 2020. © 2019 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 3, 2019; DOI: 10.1158/1535-7163.MCT-18-1378
27
with TGFβ for 48 hours. Proteins were isolated and immunoblotted with antibodies
against KLF5 and GAPDH. (B) Silencing of KLF5 sensitize smad4 deficient cells to 5-
FU with and without TGFβ treatment. Smad4 deficient cells were transfected with KLF5
shRNA’s. After transfection, cells were treated with 5-FU and TGFβ either alone or in
combination for 48 hours and analyzed for apoptosis. (C) Spheroids were generated
from Smad4 deficient cells and stemness of the isolated spheroids was verified using
cancer stem cell markers by immunoblotting. (D-E) Silencing of KLF5 decreases self-
renewal ability of spheroids. Smad4 deficient cells were transfected with KLF5 shRNA.
After transfection, cells were subjected to sphere forming assay. Spheroids in the entire
well were counted. (F) Silencing of KLF5 suppressed stemness of spheroids as
confirmed by immunoblotting using stem cell markers. (G) Overexpression of KLF5
inhibits TGFβ induced downregulation E-cadherin in smad4 proficient cells. Smad4
proficient cells were transfected with KLF5 cDNA and treated with TGFβ for 48 hours.
Proteins were isolated and immunoblotted with antibodies against E-cadherin, KLF5
and GAPDH. (H) Overexpression of KLF5 inhibits TGFβ-induced apoptosis in smad4
proficient cells. Cells after KLF5 overexpression were treated with TGFβ for 48 hours
and analyzed for apoptosis. (I) Depletion of KLF5 induces apoptosis whereas depletion
of Sox4 inhibits apoptosis after TGFβ treatment in smad4 deficient cells. Smad4
deficient cells were transfected with KLF5 and Sox4 shRNA’s. After transfection, cells
were treated with 5-FU and TGFβ for 48 hours and analyzed for apoptosis. Data
presented in the bar graphs are the mean ± SD of three independent experiments.
*Indicates a statistically significant difference compared to control with p < 0.05.
on September 30, 2020. © 2019 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 3, 2019; DOI: 10.1158/1535-7163.MCT-18-1378
on September 30, 2020. © 2019 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 3, 2019; DOI: 10.1158/1535-7163.MCT-18-1378
on September 30, 2020. © 2019 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 3, 2019; DOI: 10.1158/1535-7163.MCT-18-1378
on September 30, 2020. © 2019 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 3, 2019; DOI: 10.1158/1535-7163.MCT-18-1378
on September 30, 2020. © 2019 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 3, 2019; DOI: 10.1158/1535-7163.MCT-18-1378
on September 30, 2020. © 2019 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 3, 2019; DOI: 10.1158/1535-7163.MCT-18-1378
Published OnlineFirst May 3, 2019.Mol Cancer Ther Abdul K Siraj, Poyil Pratheeshkumar, Sasidharan Padmaja Divya, et al. in CRC
Induced SMAD4 Dependent Apoptosis Proceeded by EMTβTGF
Updated version
10.1158/1535-7163.MCT-18-1378doi:
Access the most recent version of this article at:
Material
Supplementary
http://mct.aacrjournals.org/content/suppl/2019/05/03/1535-7163.MCT-18-1378.DC1
Access the most recent supplemental material at:
Manuscript
Authoredited. Author manuscripts have been peer reviewed and accepted for publication but have not yet been
E-mail alerts related to this article or journal.Sign up to receive free email-alerts
Subscriptions
Reprints and
To order reprints of this article or to subscribe to the journal, contact the AACR Publications
Permissions
Rightslink site. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC)
.http://mct.aacrjournals.org/content/early/2019/05/03/1535-7163.MCT-18-1378To request permission to re-use all or part of this article, use this link
on September 30, 2020. © 2019 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 3, 2019; DOI: 10.1158/1535-7163.MCT-18-1378